BioPharm America™ Hot Companies
Boston is a mecca of life science innovation.
Take advantage of this unique opportunity to meet with many of the companies and executives who are helping to invent a better healthcare future.
| |
| AstraZeneca doubles down in CNS with "Neuroscience iMed" | |
While the drug development industry has seen a retrenchment of big pharma in CNS, AstraZeneca continues to provide a steady presence in the space. With the recent launch of their Neuroscience Innovative Medicines Unit (iMed), AstraZeneca aims to foment innovation in CNS by leveraging a "virtual" approach to drug discovery.
| |
| |
| Blueprint Medicines: Powerful insights and highly selective agents for cancer therapies | |
One year after the headline-grabbing start-up, Blueprint co-founder and CEO Chris Varma told partneringNEWS™ the first program to emerge from the proprietary discovery platform is now moving toward the clinic.
| |
| |
| Genocea unlocks T cell response to create new class of vaccines | |
By harnessing the T cell response to pathogens, Genocea Biosciences is developing a fresh approach to vaccine development that creates effective options to prevent or treat infectious diseases, cancers and autoimmune diseases.
| |
| |
| Epizyme: Intensive dealmaking in pursuit of personalized therapeutics | |
Little was known about the branch of epigenetics called histone methyltransferases (HMTs) when Epizyme began in late 2007. Yet before the company presented the world's first animal demonstration of efficacy for HMTs in July 2011, it had already attracted USD 54 million in venture investment and USD 45 million in funding from two pharma partners and two foundations.
| |
| |
| Forma Therapeutics: Structured acquisitions to fix broken biotech model | |
In January this year, Forma Therapeutics announced two conventional agreements for assets spinning out of its innovative discovery platform that aim for high-risk targets but hold high-reward valuations, potentially totaling USD 1.45 billion in milestone payments.
| |
| |
| Foundation Medicine: Molecular information disrupting the oncology universe | |
The news from Foundation Medicine could not be more encouraging for the company, nor more disruptive for the universe of oncology as we know it today.
| |
| |
| Joslin Diabetes Center: Building "collaboratories" for diabetes solutions | |
John Brooks has lit a fire under the Joslin Diabetes Center. Over the past year a string of announcements has flowed from the traditionally understated 114-year-old institution.
| |
